A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-resistant S. pneumoniae in Ambulatory and Hospitalized Adult Patients in the US
11 February 2021
Macrolide resistance was found in 39.5% of 3626 non duplicate Streptococcus pneumoniae isolates from adult ambulatory and inpatient settings at 329 US hospitals (2018-2019). Macrolide resistance was significantly higher for respiratory vs blood isolates and ambulatory vs inpatient admissions. Despite geographic variation, S. pneumoniae-macrolide resistance was >25% in most regions.
Further reading: Open Forum Infectious Diseases
Author(s): Vikas Gupta, Kalvin C Yu, Jennifer Schranz, Steven P Gelone
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
